Severe staphylococcal knee arthritis responding favourably to linezolid, after glycopeptide-rifampicin failure: A case report and literature review

Scandinavian Journal of Infectious Diseases

Volumn 37, Issue 6-7, 2005, Pages 513-517

  Manfredi, Roberto ^a   Sabbatani, Sergio ^a   Chiodo, Francesco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; IMIPENEM; LAMIVUDINE; LEVOFLOXACIN; LINEZOLID; METICILLIN; NELFINAVIR; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; TEICOPLANIN; TENOFOVIR; VANCOMYCIN;

ABSCESS; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL ARTHRITIS; BACTERIUM ISOLATION; BLOOD CULTURE; BONE INFECTION; CASE REPORT; DRUG PENETRATION; EVIDENCE BASED MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; KNEE ARTHRITIS; KNEE INJURY; KNEE SURGERY; LONG TERM CARE; MALE; MEDICAL LITERATURE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POSTOPERATIVE INFECTION; SEPTICEMIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; TREATMENT FAILURE;

ACETAMIDES; ANTI-BACTERIAL AGENTS; ARTHRITIS, INFECTIOUS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; TEICOPLANIN; VANCOMYCIN;

EID: 22844437733     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540510036589     Document Type: Article

References (16)

1. Mutnick AH, Biedenback DJ, Turnidge JD, Jones RN. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn Microbiol Infect Dis 2002;43:66-73.
2. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious Gram-positive infections. Drugs 2001;61:525-51.
3. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use programme. Clin Infect Dis 2003;36:159-68.
4. Howden BP, Ward PB, Charles PGP, Korman TM, Fuller A, Du Cros P, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004;38: 521-8.
5. Rayner CR, Baddour LM, Birmingham MC, Norden C, Meagher AK, Shentag JJ. Linezolid in the treatment of osteomyelitis: results of a compassionate use experience. Infection 2004;32:8-14.
6. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicentre study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003;25: 980-92.
7. Vinken AG, Li JZ, Balan DA, Rittenhouse BE, Willke RJ, Goodman C. Comparison of linezolid with oxacillin or vancomycin in the empirical treatment of cellulitis in US Hospitals. Am J Ther 2003;10:264-74.
8. Razonable RR, Osmon DR, Steckelberg JM. Linezolid therapy for orthopaedic infections. Mayo Clin Proc 2004; 79:1137-44.
9. Cepeda JA, Whitehouse T, Cooper B, Hails J, Jones K, Kwaku F, et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother 2004;53:345-55.
10. Ravindran V, John J, Kaye GC, Meigh RE. Successful use of oral linezolid as a single active agent in endocarditis unresponsive to conventional antibiotic therapy. J Infect 2003;47:164-6.
11. Rana B, Butcher I, Grigoris P, Murnaghan C, Seaton RA, Tobin CM. Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother 2002;50:747-50.
12. Kutscha-Lisssberg F, Hebler U, Muhr G, Koller M. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother 2003;47:3964-6.
13. Melzer M, Goldsmith D, Gransden W. Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving haemodyalisis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteremias. Clin Infect Dis 2000;31:208-9.
14. Rao N, Ziran BH, Hall RA, Santa ER. Successful treatment of chronic bone and joint infections with oral linezolid. Clin Orthop 2004;427:67-71.
15. Harwood PJ, Giannoudis PV. The safety and efficacy of linezolid in orthopaedic practice for the treatment of infection due to antibiotic-resistant organisms. Expert Opin Drug Saf 2004;3:405-14.
16. Nathwani D, Li JZ, Balan DA, Willke RJ, Rittenhouse BE, Mozaffari E, et al. An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects. Int J Antimicrob Agents 2004;23:315-24.